 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | CART-19/22 / Shanghai Unicar
Trial completion date, Trial primary completion date: CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. (clinicaltrials.gov) - Nov 29, 2023
P1/2, N=20, Recruiting, Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Trial completion date: Jan 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- CD22-CART / Shanghai Unicar, CART-19/22 / Shanghai Unicar
Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia (Halls G-H (San Diego Convention Center)) - Nov 3, 2023 - Abstract #ASH2023ASH_4436;
Our study showed that the second infusion of tandem CD19/CD22 CAR-T therapy obtains a better response than other infusion strategies. Bridging allo-HSCT or DAC consolidation had a significant survival benefit in patients with CR after the second CAR-T therapy.
- | CART-19/22 / Shanghai Unicar
Trial completion date, Trial primary completion date: CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. (clinicaltrials.gov) - May 19, 2022
P1/2, N=20, Recruiting, Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Bridging allo-HSCT or DAC consolidation had a significant survival benefit in patients with CR after the second CAR-T therapy. Trial completion date: Jan 2021 --> Jan 2024 | Trial primary completion date: Dec 2020 --> Dec 2023
- humanized CD19 CAR-T cells / Shanghai Unicar, CART-19/22 / Shanghai Unicar
Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_3339;
P1/2
Tandem CD19/CD22 dual targets CAR-T cells therapy obtains superior CR rate than single CD19 and sequential CD19/CD22 CAR-T cells therapy. This provides an effective treatment option for R/R B-ALL patients with chemotherapy resistance.
- CART-19/22 / Shanghai Unicar
Chimeric Antigen Receptor T Cell Targeting to CD19 and CD22 Combined with Anti-PD-1 Antibody Induce High Response in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_3314;
P2
This study suggests that CAR-T cells combined with anti-PD-1 antibody elicit a safe and durable response in R/R B-NHL. Keywords: chimeric antigen receptor modified T cell, anti-PD-1 antibody, CD19/CD22, refractory or relapsed B cell non-Hodgkin lymphoma
- | CART-19/22 / Shanghai Unicar
Trial primary completion date: CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. (clinicaltrials.gov) - Jul 15, 2019
P1/2, N=20, Recruiting, Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Keywords: chimeric antigen receptor modified T cell, anti-PD-1 antibody, CD19/CD22, refractory or relapsed B cell non-Hodgkin lymphoma Trial primary completion date: Dec 2019 --> Dec 2020
- | CART-19/22 / Shanghai Unicar
New P1/2 trial: CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. (clinicaltrials.gov) - Aug 3, 2018
P1/2, N=20, Recruiting, Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- CART-19/22 / Shanghai Unicar
New P1/2 trial, CAR T-Cell Therapy: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma (clinicaltrials.gov) - Mar 15, 2018
P1/2, N=10, Recruiting, Sponsor: Ruijin Hospital